JP2003535110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535110A5 JP2003535110A5 JP2002501260A JP2002501260A JP2003535110A5 JP 2003535110 A5 JP2003535110 A5 JP 2003535110A5 JP 2002501260 A JP2002501260 A JP 2002501260A JP 2002501260 A JP2002501260 A JP 2002501260A JP 2003535110 A5 JP2003535110 A5 JP 2003535110A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- administration
- involuntary
- contractions
- antimuscarinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/015515 WO2001093683A1 (en) | 2000-06-07 | 2000-06-07 | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012096428A Division JP2012176958A (ja) | 2012-04-20 | 2012-04-20 | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003535110A JP2003535110A (ja) | 2003-11-25 |
| JP2003535110A5 true JP2003535110A5 (https=) | 2011-09-29 |
| JP5684964B2 JP5684964B2 (ja) | 2015-03-18 |
Family
ID=21741461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501260A Expired - Fee Related JP5684964B2 (ja) | 2000-06-07 | 2000-06-07 | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286591B1 (https=) |
| JP (1) | JP5684964B2 (https=) |
| CN (3) | CN1454054A (https=) |
| AT (1) | ATE483459T1 (https=) |
| AU (2) | AU2000255966B2 (https=) |
| CA (1) | CA2378754A1 (https=) |
| DE (1) | DE60045082D1 (https=) |
| ES (1) | ES2350330T3 (https=) |
| WO (1) | WO2001093683A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516992A (ja) * | 2001-12-21 | 2005-06-09 | ブリッジ ファーマ、インコーポレイテッド | オキシブチニンの非心律動異常惹起性代謝物 |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ATE361101T1 (de) * | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
| US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
| KR20190060879A (ko) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
| US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| WO2012167212A2 (en) | 2011-06-03 | 2012-12-06 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
| US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
| US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
| US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
| CN103169660B (zh) * | 2013-04-15 | 2015-04-08 | 石正国 | 一种制备高包封率的利巴韦林脂质体口服乳 |
| JP6895252B2 (ja) * | 2013-12-18 | 2021-06-30 | サインパス ファルマ, インク.Signpath Pharma, Inc. | 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減 |
| JP2017516813A (ja) | 2014-06-03 | 2017-06-22 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果 |
| KR102638618B1 (ko) | 2016-04-27 | 2024-02-21 | 사인패스 파마 인코포레이티드 | 약물 유발된 방실 차단의 방지 |
| CA3177654A1 (en) | 2020-05-05 | 2021-11-11 | Dennis MOLNAR | Polymorphic forms of (r)-oxybutynin hydrochloride |
| TW202207952A (zh) * | 2020-07-03 | 2022-03-01 | 愛爾蘭商普候克斯根有限公司 | 病毒感染 |
| CN117396460A (zh) * | 2021-05-04 | 2024-01-12 | 爱普宁公司(特拉华) | (r)-奥昔布宁d-苹果酸盐的固体形式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008269A (en) * | 1970-05-05 | 1977-02-15 | William H. Rorer, Inc. | Phenylacetic acids |
| IT1231237B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati eterociclici |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US5973182A (en) * | 1998-10-22 | 1999-10-26 | Sepracor Inc. | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters |
-
2000
- 2000-06-07 CA CA002378754A patent/CA2378754A1/en not_active Abandoned
- 2000-06-07 WO PCT/US2000/015515 patent/WO2001093683A1/en not_active Ceased
- 2000-06-07 DE DE60045082T patent/DE60045082D1/de not_active Expired - Lifetime
- 2000-06-07 ES ES00941235T patent/ES2350330T3/es not_active Expired - Lifetime
- 2000-06-07 AT AT00941235T patent/ATE483459T1/de not_active IP Right Cessation
- 2000-06-07 AU AU2000255966A patent/AU2000255966B2/en not_active Expired
- 2000-06-07 CN CN00819623A patent/CN1454054A/zh active Pending
- 2000-06-07 JP JP2002501260A patent/JP5684964B2/ja not_active Expired - Fee Related
- 2000-06-07 EP EP00941235A patent/EP1286591B1/en not_active Expired - Lifetime
- 2000-06-07 AU AU5596600A patent/AU5596600A/xx active Pending
- 2000-06-07 CN CNA2007101418683A patent/CN101108176A/zh active Pending
-
2003
- 2003-05-16 CN CN03131438A patent/CN1451388A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003535110A5 (https=) | ||
| ES2599227T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
| US5308862A (en) | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation | |
| US7084116B2 (en) | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators | |
| JP2009526829A (ja) | 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ | |
| KR100874815B1 (ko) | 간질성 방광염 치료용 의약 조성물 | |
| AU1217697A (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| JP7748386B2 (ja) | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 | |
| JP2001515475A (ja) | 尿失禁、動揺病及びめまいの治療薬の製造のためのデスカルボエトキシロラタジンの使用 | |
| JP2004505036A5 (https=) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| RU2388466C2 (ru) | Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний | |
| EP1843765A2 (en) | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome | |
| WO1995013072A1 (en) | The use of alfuzosin or terazosin in the treatment of premature ejaculation | |
| RU2671575C2 (ru) | Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря | |
| JPH08507774A (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| ES2234933T3 (es) | Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria. | |
| KR20110005836A (ko) | 과민성 방광의 치료를 위한 유데나필과 알푸조신 또는 옥시부티닌과의 복합제의 용도 | |
| JP2549480B2 (ja) | 排尿障害改善剤 | |
| CN1625402A (zh) | 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途 | |
| WO2005007191A1 (ja) | 医薬組成物 | |
| RU2004121780A (ru) | Способ лечения | |
| JP2008506785A (ja) | インスリン抵抗性の治療及び予防のための組成物及び方法 | |
| JPS6251242B2 (https=) | ||
| CN107921011A (zh) | 逼尿肌过度活动伴收缩功能受损的改善剂 |